You should have a closer look to Kones beautiful sister. She is a little bit older, but better developed. And is able to pay dividends.
You ask dumb questions often? #1, everyone has not heard of this. When it comes to stock, trading money, your most recent question to me presupposes I should not be serious. Quite the wrong perspective you have there, impaler81. Is it time for you to frolic off somewhere? (J/K) My guess instead, you have some bashing to do.
I have found nothing. I checked the chinese Internet. Nothing. Bu CEO Tao Li has large stakes in Kone and CGA. Tao Li has a third startup, called LH900 or Jane BAi. They have contracted 200 farmers and the CEO received 500 Million US for 3 years to expand the business (gren food). I can imagine that Kone and CGA will benefit from these subsidies. It could be that Kone is involved with developing some platforms. Tao Li spoke about Win Win situations in Conjunction with CGA, but it was on the CGA conf call. I asume the same Win Win situations for Kone. Good Luck
as far as I can remember, these were the low floaters in the past few years that went from $3-5 all the way to $30 or high $20s in less than 2 weeks:
JVA, ROSG, DGLY, LIVE, VISN, USU
All have come down since then and many have issued more shares.
It seems to me KONE has the right ingredients to pull the same feat this year. VISN is chinese so KONE can be the second chinese company to join this elite group of 10-baggers
well, at least I'm hoping
"Kingtone Wirelessinfo Solution (KONE) ~ BUY ~ 5 Day Price Target: $7.60 Issued 04/09/2015 By Stock Price Target"
Hopefully. It is not the first time that Kone exploded.
When they get approval in September to launch. But also the other drugs like Humira a Biosim in partnership with Baxter has a $9 bill/year sales figure and due to being an extremely difficult and highly specialized molecule or series of molecules to manufacture there is very little if any competition. There is enormous value coming down the pike in a few years for MNTA. If they don't get swepped away with a $30plus buyout. Could be another generic trying to break into this highly lucractive space as well!
I see TEVA perhaps to protect their Copaxone franchise when Patent expires in Sep or Merck, Pfizer or any generic like Endo, Mallinkrodt seeking the BIOSIM space.
Research it this is a gold mine in two years!!! But it won't be around in two months!!